Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
8 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Sarah Cannon Research Institute at Healthone
Denver, Colorado, United States
- Florida Cancer Specialists - South
Fort Myers, Florida, United States
- Florida Cancer Specialists - North
St. Petersburg, Florida, United States
- Florida Cancer Specialists - East
West Palm Beach, Florida, United States
- Research Medical Center - Hca Midwest
Kansas City, Missouri, United States
- Tennesse Oncology
Chattanooga, Tennessee, United States
- Tennessee Oncology
Nashville, Tennessee, United States
- Medical College of Wisconsin
Milwaukee, Wisconsin, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 28 Sept 2016
- Primary completion
- 17 Aug 2022
- Completion
- 17 Aug 2022
- Last update posted
- 5 Dec 2023
- Registered enrollment
- 100
- Registry id
- NCT02795156
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.